308 related articles for article (PubMed ID: 16127030)
21. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.
Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
J Clin Microbiol; 2001 Dec; 39(12):4387-9. PubMed ID: 11724849
[TBL] [Abstract][Full Text] [Related]
22. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.
Hernandez S; López-Ribot JL; Najvar LK; McCarthy DI; Bocanegra R; Graybill JR
Antimicrob Agents Chemother; 2004 Apr; 48(4):1382-3. PubMed ID: 15047549
[TBL] [Abstract][Full Text] [Related]
23. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.
Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Holliday N; Killian SB
J Clin Microbiol; 2004 Feb; 42(2):718-21. PubMed ID: 14766842
[TBL] [Abstract][Full Text] [Related]
24. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
26. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
Odds FC; Motyl M; Andrade R; Bille J; Cantón E; Cuenca-Estrella M; Davidson A; Durussel C; Ellis D; Foraker E; Fothergill AW; Ghannoum MA; Giacobbe RA; Gobernado M; Handke R; Laverdière M; Lee-Yang W; Merz WG; Ostrosky-Zeichner L; Pemán J; Perea S; Perfect JR; Pfaller MA; Proia L; Rex JH; Rinaldi MG; Rodriguez-Tudela JL; Schell WA; Shields C; Sutton DA; Verweij PE; Warnock DW
J Clin Microbiol; 2004 Aug; 42(8):3475-82. PubMed ID: 15297486
[TBL] [Abstract][Full Text] [Related]
27. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin.
Chamilos G; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2006 Feb; 50(2):744-7. PubMed ID: 16436735
[TBL] [Abstract][Full Text] [Related]
29. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
Colombo AL; Perfect J; DiNubile M; Bartizal K; Motyl M; Hicks P; Lupinacci R; Sable C; Kartsonis N
Eur J Clin Microbiol Infect Dis; 2003 Aug; 22(8):470-4. PubMed ID: 12884068
[TBL] [Abstract][Full Text] [Related]
30. Caspofungin-induced in-vitro post-antifungal effect and its impact on adhesion related traits of oral Candida dubliniensis and Candida albicans isolates.
Ellepola AN; Chandy R; Khan ZU; Samaranayake LP
Microbiol Immunol; 2016 Mar; 60(3):160-7. PubMed ID: 26850765
[TBL] [Abstract][Full Text] [Related]
31. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts.
Park BJ; Park JC; Taguchi H; Fukushima K; Hyon SH; Takatori K
Biochem Biophys Res Commun; 2006 Aug; 347(2):401-5. PubMed ID: 16831406
[TBL] [Abstract][Full Text] [Related]
32. Caspofungin therapy of neonates with invasive candidiasis.
Odio CM; Araya R; Pinto LE; Castro CE; Vasquez S; Alfaro B; Sàenz A; Herrera ML; Walsh TJ
Pediatr Infect Dis J; 2004 Dec; 23(12):1093-7. PubMed ID: 15626944
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species.
Chryssanthou E; Cuenca-Estrella M
J Clin Microbiol; 2002 Oct; 40(10):3841-4. PubMed ID: 12354895
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates.
Maida CM; Milici ME; Oliveri S
J Chemother; 2007 Jun; 19(3):277-82. PubMed ID: 17594922
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
[TBL] [Abstract][Full Text] [Related]
36. Killing rates exerted by caspofungin in 50 % serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua.
Kovács R; Gesztelyi R; Berényi R; Domán M; Kardos G; Juhász B; Majoros L
J Med Microbiol; 2014 Feb; 63(Pt 2):186-194. PubMed ID: 24184471
[TBL] [Abstract][Full Text] [Related]
37. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species.
Barchiesi F; Schimizzi AM; Fothergill AW; Scalise G; Rinaldi MG
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):302-4. PubMed ID: 10385023
[TBL] [Abstract][Full Text] [Related]
39. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
Oliveira ER; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; Redding SW
Antimicrob Agents Chemother; 2005 Aug; 49(8):3544-5. PubMed ID: 16048980
[TBL] [Abstract][Full Text] [Related]
40. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.
Pelletier R; Alarie I; Lagacé R; Walsh TJ
Med Mycol; 2005 Sep; 43(6):559-64. PubMed ID: 16320498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
